N/A N=8 308nm Excimer Laser for Treatment of Fingernail Psoriasis
Nail Psoriasis
Primary: Modified NAPSI Score (Nail Psoriasis Severity Index) — 6.3; 6.0 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=12 A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis
Psoriatic Nail · Psoriasis Vulgaris · Psoriasis
Primary: Mean Percent Change of mNAPSI (Modified Nail Area Psoriasis Severity Index) at Week 36 Compared to Baseline for All Nails. — 64.1 percentage of reduction in mNAPSI score…
Phase 3 N=99 Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis
Chronic Plaque Psoriasis · Moderate to Severe Nail Psoriasis
Primary: The Proportion of Subjects Who Achieve at Least a 75% Improvement From Baseline in Total mNAPSI at Week 28. — 0.042; 0.255 proportion of subjects — p=0.00311
Phase 3 N=217 A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
Nail Psoriasis · Plaque Psoriasis
Primary: Percentage of Participants Achieving a Total Fingernail Modified Nail Psoriasis Severity Index (mNAPSI) 75 Response at Week 26 — 3.4; 46.6 percentage of participants…
Phase 4 N=72 Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis
Nail Psoriasis · Plaque Psoriasis
Primary: Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score for Target Fingernail — -4.32; -4.36 units on a scale — p=<0.0001
Phase 3 N=198 Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
Moderate to Severe Nail Psoriasis
Primary: Percentage Change From Baseline in Nail Psoriasis Severity Index (NAPSI) After 16 Weeks of Treatment — -38.4; -46.1; -11.7 percent change — p=<0.0001
Phase 3 N=31 Evaluation of the Efficacy and Safety of Indigo Naturalis Oil Extract on Psoriatic Nails
Nail Psoriasis
Primary: Change From Baseline in Single-Hand Nail Psoriasis Severity Index (NAPSI)and in the Modified Target NAPSI for the Single Most Severely Affected Nail of Each Hand at Week…
Phase 3 N=33 Comparison of Indigo Naturalis Oil Extract and Calcipotriol Solution in Treating Psoriasis
Nail Psoriasis
Primary: Change From Baseline in Single-handed Nail Psoriasis Severity Index (shNAPSI) at 24 Weeks — 27.2; 27.4; 14.4; 20.4 units on a scale
Phase 2 N=21 Topical Cyclosporine Suspension for the Treatment of Brittle Nails
Brittle Nail Syndrome
Primary: • Number of Patients Receiving at Least a 1-grade Improvement in the Physicians Global Improvement Assessment (PGIA) of Two Target Nails. — 10; 11 patients
Phase 4 N=55 Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis
Nail Psoriasis · Nail Diseases
Primary: Lowest Effective Concentration of Intralesional Triamcinolone Acetonide for Nail Psoriasis — 2.5 mg/mL
Phase 4 N=6 A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis
Nail Psoriasis
Primary: Clinical Improvement in Nail Thickness of Target Nail at Week 24 Compared to Baseline. — 2 Participants who experienced improvement
Phase 4 N=22 Use of Platelet-rich Plasma (PRP) Therapy in Patients With Brittle Nail Syndrome
Nail Diseases
Primary: Physician Global Improvement Assessment (PGIA) — 5; 2; 7; 1 Fingernails
N/A N=506 Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice
Moderate to Severe Plaque Psoriasis
Primary: Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) to Month 12 — -74.6 percent change
N/A N=21 Psoriasis Inflammation and Systemic Co Morbidities
Psoriasis
Primary: Change in Histology
Phase 4 N=6 Can We Miss Pigmented Lesions in Psoriasis Patients?
Psoriasis · Melanoma · Non-melanoma Skin Cancer
Primary: The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques. — 0 participants
Phase 4 N=100 Apremilast in Palmo-Plantar Psoriasis
Palmo-plantar Psoriasis
Primary: Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0 or 1 — 7; 2 Participants
Phase 3 N=24 Safety and Efficacy of Infliximab in Palmoplantar Psoriasis
Palmoplantar Psoriasis
Primary: 75% Improvement in Modified Palmoplantar Pustulosis Area and Severity Index (m-PPPASI) From Day 0 — 1; 4 Participants
Phase 4 N=1,013 Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice
Psoriasis · Psoriatic Arthritis
Primary: Percentage of Participants With Psoriatic Arthritis (PsA) Based on Physical Examination, Medical History and Laboratory Results — 30.0 Percentage of participants
Phase 4 N=11 Evaluating the Efficacy and Tolerability of Application of Metaderm Product for the Treatment of Psoriasis
Psoriasis
Primary: Efficacy as Measured by the Mean Percentage Change in the Product of Static Physician Global Assessment (sPGA) and Body Surface Area (BSA). — 53.06; 65.6 percentage of…
Phase 2 N=24 A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris
Psoriasis Vulgaris
Primary: Absolute Change in Total Clinical Score (TCS) of Clinical Signs (Sum of Erythema, Scaling and Infiltration) at End of Treatment Compared to Baseline — -6.00; -4.96…
Phase 4 N=124 Moderate to Severe Plaque Psoriasis With Scalp Involvement
Psoriasis
Primary: Percentage Change From Baseline in Psoriasis Scalp Severity Index at Week 12 — 20.4; 86.8 Percent change — p=<0.0001
N/A N=103 Improvement of Psoriasis Patients' Adherence to Topical Drugs
Psoriasis Vulgaris
Primary: Severity of Psoriasis — 2.68; 1.84 units on a scale
Phase 3 N=15 A Placebo-Controlled Double-Blind Study on the Safety and Efficacy of Etanercept in Palmoplantar Pustulosis
Palmoplantaris Pustulosis
Primary: Percentage Change in Palmoplantar Pustulosis Severity Index (PPPASI) Before Crossover — 30.1; 7.1 Percentage change
N/A N=34 Psoriasis Microbiome and Phototherapy
Psoriasis
Primary: Cutaneous Microbiota Shannon's Alpha Diversity at Baseline — -0.05; 0.06; -0.06; 0.12 Shannon's index
Phase 2 N=259 Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis
Moderate to Severe Plaque Psoriasis
Primary: Percentage of Participants Who Achieved at Least 75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12 — 5.8; 18.0; 44.2…
Phase 4 N=29 Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis
Plaque Psoriasis
Primary: Number of Participants Maintaining Psoriasis Area Severity Index Score (PASI) 75 at Week 36 — 4; 2 participants
Phase 4 N=20 Topical Psoriasis Study for Patients Receiving Biologic Therapy
Psoriasis
Primary: Psoriasis Severity — 4.25 units on a scale
N/A N=171 Psoriatic Arthritis Research Collaborative: Biologic Sub-Study
Psoriatic Arthritis
Primary: Patient Function Response to Biologic Therapy as Measured by RAPID3 — -1.11 change in score
Phase 2 N=81 Topical CP-690,550 For Chronic Plaque Psoriasis
Psoriasis
Primary: Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4 — 2.38; -4.76; 2.48; -4.17 Percent Change
N/A N=29 Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis
Psoriasis · Atherosclerotic Cardiovascular Disease · Obesity
Primary: Mean Change in the TH17 Cell Cytokine IL-17 Secretion in Response to T-cell Differentiation — -176.9; -7.2 pg/mL — p=0.01